Endothelin (ET) is a recently discovered ... heart failure and the available information concerning the use of ET receptor antagonists in treating this condition.

Are selective endothelin-receptor antagonists really an important new advance for treating patients with treatment-resistant hypertension? The evidence from a recent study leaves us with some ...

ASCEND was a multicenter, placebo-controlled trial that aimed to investigate the effects of the endothelin-A (ET A) receptor antagonist avosentan in patients with diabetic nephropathy. The study ...

The dual endothelin receptor antagonist (ERA) has been tipped as a potential $2.5 billion blockbuster by analysts at Jefferies, as there is considerable need for new therapies for people with so ...

Combination regimens based on SGLT2 inhibitors and two drugs with different mechanisms of action have shown activity ... with zibotentan, an endothelin A (ETA) receptor antagonist, on levels ...